Clinical trials: Pulmonary Resistance
Ventilator Associated Pneumonia, Multi-antibiotic Resistance
Use of Aaerosol Combined With Intravenous Antibiotics for the Treatment of Multidrug Resistant GNB Pneumonia
To investigate use of aerosol combined with intravenous antibiotics for the treat of multi-drug resistance gram negative bacterias diagnosed ventilator-associated pneumonia in intensive care unit in a hospital.
- Trial name
- ACAMP (NCT03921645)
- Testing
- aerosol antibiotics
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai 10th People's Hospital
Mechanical Ventilation, Pneumonia
Removal of Endotracheal Tube Secretions Comprehensively Until Extubation
The purpose of this study is to measure secretion accumulation within endotracheal tubes of mechanically ventilated patients and test the efficacy, safety and clinical impact of removing the secretions using novel airway…
- Trial name
- RESCUE (NCT00663637)
- Testing
- CAM (Complete Airway Management) Catheters
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- O. M. Neotech, Inc.
Cystic Fibrosis-related Diabetes
EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis
Cystic Fibrosis Related Diabetes has been identified by the CF community as one of the top ten priorities for CF research. In CF clinical decline due to dysglycemia begins early, prior to diagnosis of diabetes and increases…
- Trial name
- NCT03650712
- Testing
- Oral glucose tolerance test, Continuous glucose monitoring, Dexa scan
- Where
- 4 sites in United States
- Volunteers
- 317 people
- Sponsor
- Katie Larson Ode
Non-small Cell Lung Cancer
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity
DARWIN II is a multi-arm non-randomised phase II trial, Eligible patient will be those who relapse with NSCLC (clinical trials.gov ref. NCT02183883). .
- Trial name
- DARWINII (NCT02314481)
- Testing
- MPDL3280A, Vemurafenib, Alectinib
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Cystic Fibrosis
Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified
Antimicrobial resistance is a significant challenge facing global healthcare. The unnecessary use of antibiotics is a key driver in the development of antibiotic resistance.
- Trial name
- CFMATTERS (NCT02526004)
- Testing
- Ceftazidime, Tobramycin
- Where
- Ireland
- Volunteers
- 223 people
- Sponsor
- University College Cork
Lung, Carcinoma
Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer
Epidermal growth factor receptor (EGFR) tyrosine kinase is one of most popular target molecules in the field of anticancer drug research.
- Trial name
- NCT02139579
- Testing
- Bevacizumab
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
EGFR-TKI Resistant Mutation
Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)
EGFR-TKI is the main is the first line therapy for local advanced or metastatic non-small cell lung cancer with EGFR gene mutation. The median progression free survival time is around 11 months with the first generation EGFR-TKI.
- Trial name
- NCT02575560
- Testing
- history data
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Qingdao Central Hospital
Advanced Cancer
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.
- Trial name
- NCT04148937
- Testing
- LY3475070, Pembrolizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Ventilator Associated Pneumonia
7-days Versus 14 Days of Antibiotics Therapy for Ventilator Associated Pneumonia
There is evidence that using shorter antibiotic regimens may help in decreasing antimicrobial resistance and reducing drug-related adverse events.6 Moreover, short-course treatments were found to be as effective as longer-course…
- Trial name
- NCT03477292
- Testing
- Duration of antibiotic
- Where
- 2 sites in India
- Volunteers
- 41 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Multi-drug Resistant Tuberculosis
Post Marketing Registry to Assess Usage, Safety and Effectiveness of Deltyba Tablets in Korean Patients With MDR-TB
Deltyba Registry aims to collect the usage information of Deltyba which could be a factor of developing resistance in actual clinical settings.
- Trial name
- NCT03470233
- Where
- 2 sites in South Korea
- Volunteers
- 149 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Metastatic Cancer, Prostate Cancer
Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01160705
- Testing
- docetaxel, RNA analysis, reverse transcriptase-polymerase chain reaction
- Where
- 5 sites in Ireland
- Volunteers
- 73 people
- Sponsor
- Cancer Trials Ireland
COPD
Association Between Handgrip Strength and Small Airway Disease in Patients with Stable Chronic Obstructive Pulmonary Disease
The goal of this observational study is to investigate the correlation between handgrip strength and small airway disease among patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT06223139
- Testing
- Handgrip strength
- Where
- Thailand
- Volunteers
- 64 people
- Sponsor
- Thammasat University
Pulmonary Disease, Chronic Obstructive
Single Limb Resistance Training in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The chronic airflow limitation in chronic obstructive pulmonary disease (COPD) patients resulting in increased dyspnea during physical activity restricts many COPD patients ability to perform exercises in general and whole-body…
- Trial name
- COPD (NCT01354067)
- Testing
- Control group, High-repetitive single limb training
- Where
- 2 sites in Sweden
- Volunteers
- 44 people
- Sponsor
- Umeå University
Major Depressive Disorder, Recurrent, Unspecified
Deep Brain Stimulation of Nucleus Accumbens for Chronic and Resistant Major Depressive Disorder
Depression is a common, recurrent and disabling disorder. Among patients with a chronic course of the disease, 20 to 30% are resistant to antidepressant medications.
- Trial name
- PRESTHYM (NCT01569711)
- Testing
- Deep brain stimulation of nucleus accumbens
- Where
- 10 sites in France
- Volunteers
- 6 people
- Sponsor
- Rennes University Hospital
NSCLC Stage IV, NSCLC Stage IIIB
Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)
This phase Ib/II trial studies how well cadonilimab combined with anlotinib and docetaxel work in treating patients with non-small cell lung cancer that is stage IV or has come back.
- Conditions
- NSCLC Stage IV, NSCLC Stage IIIB, NSCLC Stage IIIC
- Trial name
- AK104IIT018 (NCT05816499)
- Testing
- Cadonilimab, Anlotinib, Docetaxel
- Where
- 5 sites in China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Pulmonary Arterial Hypertension
Estimation of Pulmonary Vascular Resistance by Contrast Echocardiography
An echocardiogram using Definity contrast can provide the same information as the standard right heart catheterization.
- Trial name
- NCT02028299
- Testing
- 2D doppler echo with Definity solution
- Volunteers
- 38 people
- Sponsor
- George Washington University
Tuberculosis
To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.
The purpose of this study is to evaluate the safety, tolerability and effectiveness of TMC207 in combination with an individualized background regimen (BR) of antibacterial drugs as treatment for MDR-TB
- Trial name
- NCT00910871
- Testing
- TMC207, Background Regimen (BR) for MDR-TB
- Where
- 27 sites in China, Estonia and 10 more
- Volunteers
- 241 people
- Sponsor
- Janssen Infectious Diseases BVBA
Lung Neoplasms, EGFR Gene Mutations
Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring activating epidermal growth factor receptor (EGFR) mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from…
- Trial name
- LiquidLung-O (NCT02769286)
- Testing
- Osimertinib
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Chonnam National University Hospital
EGFR-TKI-resistant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer
This study is a Phase I, single-arm, single-center, dose-escalation clinical trial designed to investigate the safety and efficacy of intrathecal injection of sacituzumab tirumotecan (sac-TMT) in patients with EGFR…
- Trial name
- NCT07702305
- Testing
- Sacituzumab tirumotecan
- Volunteers
- 15 people
- Sponsor
- Henan Cancer Hospital
Non Small Cell Lung Cancer
Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.
This study is to evaluate the preliminary efficacy and safety of Chidamide combined with Envafolimab in patients with PD-1 inhibitor resistant advanced NSCLC.
- Trial name
- NCT05068427
- Testing
- Chidamide, Envafolimab
- Where
- 12 sites in China
- Volunteers
- 34 people
- Sponsor
- Chipscreen Biosciences, Ltd.